Entera Bio Ltd. (ENTX) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$3.07

From 52W high−24.49%

Volume288961.00

Market cap$512.50M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

$3.07

From 52W high

−24.49%

Volume

288961.00

Market cap

$512.50M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−35.2x

P/E (TTM)

—

RSI (14)

52.0

MomentumView details →

1D Return

−2.31%

YTD Return

+51.80%

SummaryUpdated Jun 1, 2026

Entera Bio Ltd. (NASDAQ:ENTX) is a clinical-stage biopharmaceutical company founded in 2009 and headquartered in Jerusalem, Israel. The company went public in June 2018 and specializes in developing oral delivery technologies for large molecule therapeutics, particularly focusing on treatments for bone-related disorders and other unmet medical needs. Entera Bio has established itself as a pioneer in the challenging field of oral delivery of large molecules, which traditionally require injection due to their poor absorption when taken orally.

Ask drillr about Entera Bio Ltd. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−35.2x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

70.5x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−234.42%

ROA (TTM)

−87.44%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

−100.00%

EPS YoY

—

FCF YoY

−70.26%

Revenue CAGR 3Y

−32.07%

EPS CAGR 3Y

+0.00%

EBITDA YoY

−35.26%

MomentumView details →

1D Return

−2.31%

YTD Return

+51.80%

1Y Return

+63.61%

RSI (14)

52.0

vs 50D SMA

+6.52%

vs 200D SMA

+66.64%

Capital & dividendView details →

Debt/Equity

0.06x

Current Ratio

8.98x

Quick Ratio

8.98x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.14

EPS Surprise

−75.00%

Beats (12Q)

9/12

Next Q EPS Est

−$0.08

Avg Surprise (4Q)

−4.51%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−17.03M

Op. CF (TTM)

−11.32M

Next earningsNov 13, 2026 →

Latest newsMore news →

Entera Bio Ltd. priced an oversubscribed $275 million private placement led by existing investor BVF Partners L.P.55d ago

Similar companies

Contineum Therapeutics, Inc. Class A Common StockCTNM Autolus Therapeutics plcAUTL Assembly Biosciences, Inc.ASMB MapLight Therapeutics, Inc.MPLT XOMA Royalty Corp.XOMA Ovid Therapeutics Inc.OVID Find similar companies →

Latest newsMore news →

Entera Bio announced plans to start a Phase 3 registrational trial for its oral osteoporosis drug EB613 after reaching agreement with the U.S. FDA on a 12-month placebo-controlled study design.38d ago Entera Bio Ltd. priced an oversubscribed $275 million private placement led by existing investor BVF Partners L.P.55d ago